Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

While the news isn’t great for vaccine manufacturers, it could have been worse. Shares of pure vaccine play Moderna rose 0.3% ...

Science came to life as curious young minds took center stage at the Pfizer School of Science Mobile Experience, a hands-on ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Recipients of the Pfizer mRNA vaccine experienced more all-cause deaths within the first 100 days post-vaccination than ...

The legal action follows a 2024 French study that found that the use of medroxyprogesterone renders a woman five times more likely to develop a meningioma brain tumor.

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...